Tokyo staged a rally in the week ended August 11, following seesaw movements. The Nikkei 225 rose 3.8%, recovering the critical 13,000 level at the close, while the Topix index was up 2.6%. The review week's first four sessions saw rather directionless developments because of a lack of new incentives and trading ideas. Investors were discouraged by the government's presentation of a bearish forecast for Japan's capital spending, projecting a 3.0% drop quarter-on-quarter in machinery orders in the July-September period. However, the market rebounded on the last trading day aided by the yen's depreciation against the US dollar, prompting players to purchase export-oriented issues. The pharmaceutical index was up 1.1%, underperforming the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze